Effect of magnesium oxide supplementation on the gene expression associated with insulin, lipid and inflammatory metabolism in diabetic hemodialysis patients

Investigation of the Effect of magnesium oxid supplementation on gene expression levels associated with insulin, lipid and inflammatory metabolism in diabetic hemodialysis patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20190912044757N1

Enrollment

Registered

2019-11-23

Start date

2019-07-09

Completion date

Unknown

Last updated

2019-12-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hemodialysis. End stage renal disease

Interventions

Intervention 1: Intervention group: administration of magnesium oxide (Barij Essence Co. Kashan, Iran), 250 mg, daily, for 24 weeks, orally. Intervention 2: Control group: Placebo (Barij Essence, Kash

Eligibility

Sex/Gender

All

Age

45 Years to 75 Years

Inclusion criteria

Inclusion criteria: ?Diabetic Hemodialysis patients with glomerular filtration less than 10 or less than 25 ml / min with malnutrition or hyperkalemia Age 45-75 years No smoking Moderate hypertension (systolic blood pressure between 160-140 mmHg and diastolic blood pressure between 90-100 mmHg)

Exclusion criteria

Exclusion criteria: Unwillingness to participate in the study Hypothyroidism or hyperthyroidism (clinical evaluation by a specialist physician and laboratory test) Specific illness that may lead to hospitalization High blood pressure (systolic pressure above 160 and diastolic pressure above 100 mm Hg)

Design outcomes

Primary

Measure	Time frame
Expressed levels of proliferator-activated receptor gamma (PPAR-?) gene. Timepoint: At the beginning of the study (before intervention) and after 6 months of intervention. Method of measurement: Reverse Transcriptase polymerase chain reaction (RT-PCR) technique.	—

Secondary

Measure	Time frame
Expressed levels of oxidized low-density lipoprotein (LDL-ox) gene. Timepoint: At the beginning of the study (Before intervention) and after 6 months of intervention. Method of measurement: Reverse Transcriptase polymerase chain reaction (RT-PCR) technique.;Expressed levels of vascular endothelial growth factor (VEGF) gene expression. Timepoint: At the beginning of the study (Before intervention) and after 6 months of intervention. Method of measurement: Reverse Transcriptase polymerase chain reaction (RT-PCR) technique.;Expressed levels of Transforming growth factor ß (TGF-ß) gene. Timepoint: At the beginning of the study (Before intervention) and after 6 months of intervention. Method of measurement: Reverse Transcriptase polymerase chain reaction (RT-PCR) technique.;Expressed levels of Transforming growth factor a (TGF-a) gene. Timepoint: At the beginning of the study (Before intervention) and after 6 months of intervention. Method of measurement: Reverse Transcriptase polymerase chain reaction (RT-PCR) technique.;Expressed levels of Interleukin-8 (IL-8) gene. Timepoint: At the beginning of the study (Before intervention) and after 6 months of intervention. Method of measurement: Reverse Transcriptase polymerase chain reaction (RT-PCR) technique.;Expressed levels of Interleukin-1 (IL-1) gene expression. Timepoint: At the beginning of the study (Before intervention) and after 6 months of intervention. Method of measurement: Reverse Transcriptase polymerase chain reaction (RT-PCR) technique.	—

Measure

Time frame

Expressed levels of oxidized low-density lipoprotein (LDL-ox) gene. Timepoint: At the beginning of the study (Before intervention) and after 6 months of intervention. Method of measurement: Reverse Transcriptase polymerase chain reaction (RT-PCR) technique.;Expressed levels of vascular endothelial growth factor (VEGF) gene expression. Timepoint: At the beginning of the study (Before intervention) and after 6 months of intervention. Method of measurement: Reverse Transcriptase polymerase chain reaction (RT-PCR) technique.;Expressed levels of Transforming growth factor ß (TGF-ß) gene. Timepoint: At the beginning of the study (Before intervention) and after 6 months of intervention. Method of measurement: Reverse Transcriptase polymerase chain reaction (RT-PCR) technique.;Expressed levels of Transforming growth factor a (TGF-a) gene. Timepoint: At the beginning of the study (Before intervention) and after 6 months of intervention. Method of measurement: Reverse Transcriptase polymerase chain reaction (RT-PCR) technique.;Expressed levels of Interleukin-8 (IL-8) gene. Timepoint: At the beginning of the study (Before intervention) and after 6 months of intervention. Method of measurement: Reverse Transcriptase polymerase chain reaction (RT-PCR) technique.;Expressed levels of Interleukin-1 (IL-1) gene expression. Timepoint: At the beginning of the study (Before intervention) and after 6 months of intervention. Method of measurement: Reverse Transcriptase polymerase chain reaction (RT-PCR) technique.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZatollah Asemi

Kashan University of Medical Sciences

asemi_z@kaums.ac.ir+98 31 5546 3378

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026